NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00094497,Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT),https://clinicaltrials.gov/study/NCT00094497,,COMPLETED,"The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable to complete surgical resection.",YES,"Carcinoma, Adrenal Cortical",DRUG: Etoposide|DRUG: Doxorubicin|DRUG: Cisplatin|DRUG: Streptozotocin|DRUG: Mitotane,"Overall Survival, participants who died among those randomized to first-line therapy, every 8 weeks until death up to 5 years","Progression-free Survival, every 8 weeks until progression or death up to 5 years|Change in Quality of Life as Measured by QLQ-C30, scale ranged from 0 to 100 with higher score meaning greater quality of life, baseline and 8 weeks|Best Overall Response Rate, RECIST 1.0 was used to evaluate response, every 8 weeks up to 5 years|Number of Disease-free Patients, complete response or disease-free by time of surgery, every 8 weeks until progression (up to 5 years)","TTP of Both Regimens as Second Line Treatment in Case of Failure of the Other Initial Regime, every 8 weeks until progression or until Dec 2010|Pharmakinetics of Mitotane (Substudy), To study the relationship between mitotane dose (daily and cumulative) and mitotane plasma concentrations using one of two pre-defined treatment regimens (high-dose and low-dose)., 11 time points in the first 12 weeks|Impact of Reaching Mitotane Blood Levels Between 14-20 mg/l in Both Arms on Survival and Overall Response Rate, every 8 weeks until progression or until Dec 2010",Collaborative Group for Adrenocortical Carcinoma Treatment,German Federal Ministry of Education and Research|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE3,304,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CO-ACT-001,2004-06,2010-12,2010-12,2004-10-20,2016-09-21,2016-09-21,"National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States|University of Michigan, Department of Internal Medicine, Ann Arbor, Michigan, 48109, United States|Royal Adelaide Hospital, Adelaide, SA 5000, Australia|University of Graz, Graz, 8036, Austria|Clinique Marc Linquette, Lille, France|Centre Leon Berard, Lyon, France|Hospital de Marseille la timone, Marseille, 13385, France|Cochin Hospital, Paris, 75679, France|Hospital Bordeaux haut leveque, Pessac, 33600, France|Institut Gustave Roussy, Villejuif, 94805, France|Charité-University, Dept. of Endocrinology; Campus Benjamin Franklin, Berlin, Germany|Charité-Universitätsmedizin Berlin - Campus Mitte, Berlin, Germany|Dept. of Medicine III, Dresden, Germany|University of Duesseldorf, Dept. of Endocrrinology, Duesseldorf, 40001, Germany|Zentrum für Innere Medizin - Endokrinologie des Universitätsklinikum Essen, Essen, Germany|Endokrinologie Medizinische Hochschule Hannover, Hannover, Germany|Otto-von-Guericke University; Dept. of Endocrinology, Magdeburg, 39120, Germany|Dept of Medicine I, Mainz, Germany|University of Munich, Dept. of Internal Medicine (Innenstadt), Munich, 80336, Germany|University of Wuerzburg - Dept. of Medicine, Wuerzburg, 97080, Germany|University of Turin, Dept of Internal Medicine, Orbassano, 10043, Italy|Clinica Endocrinologica, Università di Padova, Azienda Ospedaliera di Padova, Padova, Italy|Vrije Universiteit Medisch Centrum, Amsterdam, 1007, Netherlands|Academisch Medisch Centrum; Dept. of Endocrinology, Amsterdam, 1105 AZ, Netherlands|Maxima Medisch Centrum; Dept. of Internal Medicine, Eindhoven, 5631 BM, Netherlands|University Hospital Groningen; Dept. of Internal Medine, Groningen, 9700, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden|Department of Oncology, Linköping University Hospital, Linköping, Sweden|Department of Medicine, The Jubileum Institute, Lund University, Lund, Sweden|Dept of Surgery, Karolinska Hospital, Stockholm, Stockholm, Sweden|Uppsala University Hospital - Dept of Medical Sciences, Uppsala, 751 85, Sweden",
